التفاصيل البيبلوغرافية
| العنوان: |
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects |
| المؤلفون: |
Kraft, WK, Gilmartin, JH, Chappell, DL, Gheyas, F, Walker, BM, Nagalla, S, Naik, UP, Horrow, JC, Wrishko, RE, Zhang, S, Anderson, MS |
| المساهمون: |
Merck |
| المصدر: |
Clinical and Translational Science ; volume 9, issue 4, page 221-227 ; ISSN 1752-8054 1752-8062 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2016 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
The effect of the protease‐activated receptor‐1 (PAR‐1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two‐period, open‐label trial in healthy men ( n = 31) and women ( n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady‐state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed. Bleeding time geometric mean ratio (90% CI) for vorapaxar/baseline was 1.01 (0.88–1.15), aspirin/baseline was 1.32 (1.15–1.51), vorapaxar + aspirin/vorapaxar was 1.47 (1.26–1.70), and vorapaxar + aspirin/aspirin was 1.12 (0.96–1.30). Unlike aspirin, vorapaxar did not prolong bleeding time compared with baseline. Bleeding time following administration of vorapaxar with aspirin was similar to that following aspirin alone. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1111/cts.12405 |
| الإتاحة: |
https://doi.org/10.1111/cts.12405Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: |
edsbas.7DB0CC15 |
| قاعدة البيانات: |
BASE |
